Table of Content

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Isothermal Nucleic Acid Amplification Technology Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of Covid-19
5.4 Market Forecast

6 Market Breakup by Product
6.1 Instruments
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Reagents
6.2.1 Market Trends
6.2.2 Market Forecast

7 Market Breakup by Technology
7.1 Helicase-Dependent Amplification (HDA)
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Nicking Enzyme Amplification Reaction (NEAR)
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Loop-Mediated Isothermal Amplification (LAMP)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Strand Displacement Amplification (SDA)
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Nucleic Acid Sequence-Based Amplification (NASBA)
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Transcription Mediated Amplification (TMA)
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Single Primer Isothermal Amplification (SPIA)
7.7.1 Market Trends
7.7.2 Market Forecast
7.8 Others
7.8.1 Market Trends
7.8.2 Market Forecast

8 Market Breakup by Application
8.1 Infectious Disease Diagnosis
8.1.1 Market Trends
8.1.2 Major Types
8.1.2.1 Hepatitis
8.1.2.2 CT/NG
8.1.2.3 HIV
8.1.2.4 Influenza
8.1.2.5 Others
8.1.3 Market Forecast
8.2 Blood Screening
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by End-User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Diagnostic Laboratories
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Research Laboratories
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast

10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast

11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 bioM?rieux
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 BD (Becton, Dickinson and Company)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Eiken Chemical Co. Ltd
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Hologic Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Meridian Bioscience Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 OptiGene Limited
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8 Thermo Fisher Scientific Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Tecan Trading AG
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Ustar Biotechnologies Ltd.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio